Biogen tapped Viehbacher as CEO for his ability to rebuild post their looming patent cliff.
Viehbacher is the rare pharma executive who has a keen understanding of the complexities involved in running a multibillion-dollar global pharma business as well as a deep appreciation for the value of innovation.
Viehbacher’s ability to diversify assets by deftly navigating M&A and refocusing R&D, combined with rigorous cost control, will enable him to lead Biogen to sustainable, long-term growth.
Our investigative journalists interview the top former colleagues of the CEOs you care about.
Our former buysider analysts summarize the key strengths & weaknesses, past successes & failures, and ability to drive value going forward.
You get access to the actual anonymized transcripts and insights.